MRMarika Rudler

Marika Rudler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marika Rudler has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Dominique Thabut

    Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Hepatology Department, Paris, France; INSERM, Centre de Recherche Saint-Antoine (CRSA), Institute of Cardiometabolism and Nutrition (ICAN), Paris, France

    32 shared publications
  • Dominique Thabut

    Brain-Liver Pitié Salpêtrière (BLIPS) Study Group, APHP Sorbonne Université, Centre de Recherche Saint-Antoine, Maladies Métaboliques, Biliaires Et Fibro- Inflammatoire du Foie, INSERM UMR_S 938, Paris, France

    16 shared publications
  • Charlotte Bouzbib

    AP-HP, Sorbonne Université, Liver Intensive Care Unit, Hepatogastroenterology Department, La Pitié-Salpêtrière Hospital, Paris, France; INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France

    10 shared publications
  • Philippe Sultanik

    AP-HP, Sorbonne Université, Liver Intensive Care Unit, Hepatogastroenterology Department, La Pitié-Salpêtrière Hospital, Paris, France; INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France

    9 shared publications
  • Maxime Mallet

    Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Hepatology Department, Paris, France

    8 shared publications
  • Nicolas Weiss

    Sorbonne Université, AP-HP.Sorbonne Université, Hopital Pitié-Salpétrière, Paris, France

    7 shared publications

Latest Publications

  • Open Access

    Pre‐ TIPS Liver and Spleen Volumetry Are Not Associated With Liver‐Related Outcomes After TIPS Placement for Refractory Ascites

    by José Ursic Bedoya, Mathilde Wagner, Emilie Malézieux, Paul Primard, Hélène Larrue, Sarah Mouri, Charlotte Bouzbib, Marion Soler, Christophe Bureau, Nicolas Molinari, et al.

    Background & Aims: Transjugular intrahepatic portosystemic shunt (TIPS) improves survival in refractory ascites. A careful patient's selection is mandatory as TIPS can lead to complications. Liver volumetry is predictive of outcomes before hepatic surgery, but data on its role before TIPS placement are scarce. We aimed to evaluate whether liver and spleen volume measurements are associated with prognosis after TIPS placement in patients with ascites. Methods: We analysed data from three French centers, treated with TIPS between 2017 and February 2022. Inclusion criteria encompassed a TIPS placement for refractory or recurrent ascites and availability of cross‐sectional imaging. Exclusion criteria included non‐cirrhotic portal hypertension, other indications for TIPS, hepatocellular carcinoma beyond Milan criteria, and extrahepatic malignancy. Liver and spleen volumes were measured using pre‐TIPS CT or MRI scans. The primary endpoint was 1‐year transplant‐free survival (TFS). Secondary endpoints were overt hepatic encephalopathy (HE), recurrence of ascites, acute variceal bleeding, and jaundice. Results: The 160 patients were included (median age 60 years, male gender 83.8%, alcohol‐related cirrhosis 58.8%, with active alcohol consumption in 25.6%, Child‐Pugh B cirrhosis in 81.2%, median MELD score was 12). The 1‐year TFS was 60.1%. Multivariate analysis identified serum creatinine (HR = 1.01 95% CI [1.00–1.01], p = 0.04), total bilirubin (HR = 1.02 95% CI [1.02–1.04], p = 0.004), and portal pressure gradient (HR = 1.09 95% CI [1.01–1.18], p = 0.03) as independent factors associated with TFS. Neither liver‐to‐spleen volume ratios (LSVR) ( p = 0.36) nor liver volume index ( p = 0.92) were significantly associated with death or LT. Overall, 38.1% of patients developed overt HE after TIPS, with lower platelet count (HR = 1.01 95% CI [1.00–1.01], p = 0.04) emerging as an independent predictor. No radiological characteristics were associated with the recurrence of ascites. Conclusions: In this multicenter study, liver and spleen volumes were not associated with transplant‐free survival or liver‐related outcomes in patients undergoing TIPS for ascites. These findings suggest that liver volumetry should not be a determining factor in patient selection for TIPS placement.


  • Open Access

    Interobserver agreement in the assessment of active bleeding at endoscopy in patients with cirrhosis and acute variceal bleeding

    by Simona Tripon, Amine Benmassaoud, Maxime Mallet, Dominique Thabut, Marika Rudler

  • Open Access

    Corrigendum to ‘Pre-emptive TIPS should be considered in high-risk patients with both acute variceal bleeding and severe alcohol-related hepatitis’ (JHEP Reports 7 [2025] 101611)

    by Marika Rudler, Virginia Hernández-Gea, Hélène Larrue, Charlotte Bouzbib, Bogdan Procopet, Anna Baiges, Fanny Turon, Candido Villanueva, Agustin Albillos, Edilmar Alvarado Tapias, et al.

  • Open Access

    Animal naming test at discharge is associated with hepatic encephalopathy after elective TIPS

    by Melisande Jorus, Philippe Sultanik, Charlotte Bouzbib, Sarah Mouri, Lyes Kheloufi, Maxime Gasperment, Nicolas Weiss, Charles Roux, Dominique Thabut, Marika Rudler

  • Open Access

    Pre-emptive TIPS should be considered in high-risk patients with both acute variceal bleeding and severe alcohol-related hepatitis

    by Marika Rudler, Virginia Hernández-Gea, Hélène Larrue, Charlotte Bouzbib, Bogdan Procopet, Anna Baiges, Fanny Turon, Candido Villanueva, Agustin Albillos, Edilmar Alvarado Tapias, et al.


  • Open Access

    Overt hepatic encephalopathy after elective and preemptive TIPS: Risk factors and prognosis

    by Marika Rudler, Charlotte Bouzbib, Philippe Sultanik, Charles Roux, Paul Primard, Mélisande Jorus, Lyes Kheloufi, Nicolas Weiss, Asier Rabasco Meneghetti, Benjamin Poussot, et al.


  • Open Access

    Multiple Concomitant Precipitating Factors of Hepatic Encephalopathy Are Associated With a Poor Prognosis in Patients With Cirrhosis Admitted to Intensive Care Unit

    by Marika Rudler, Marie de Matharel, Charlotte Bouzbib, Sarah Mouri, Lyes Kheloufi, Nicolas Weiss, Philippe Sultanik, Dominique Thabut

    Introduction: Management of hepatic encephalopathy relies on the identification and control of precipitating factors (PF). The prognostic value of a PF is unknown, which we aimed to explore. Patients and Methods: Single‐center retrospective study of cirrhotic patients included in a prospective cohort admitted to an intensive care unit (ICU) between 2019 and 2022. Inclusion criteria: cirrhosis; overt hepatic encephalopathy; ammonemia ≥ 50 μmol/L. PF considered: gastrointestinal bleeding, infection, acute renal injury (AKI), hyponatremia, constipation, non‐adherence to ammonia‐lowering therapy, TIPS, drugs precipitating overt hepatic encephalopathy. The primary endpoint was 1‐year transplant‐free survival (TFS). Secondary endpoint was recurrence of hepatic encephalopathy. Results: 179/497 patients were included (men 72%, age 59, cause of cirrhosis alcohol (ALD)/metALD/MASLD/other in 41/21/6/32%, Child–Pugh A/B/C in 1/18/81%, West Haven grade 2/3/4 in 63/15/22%, MELD score 23). Reasons for admission were: gastrointestinal bleeding (31%), acute encephalopathy (28%), worsening liver function/jaundice (25%), infection (8%), and AKI (8%). All patients (100%) had at least one PF of hepatic encephalopathy (infection [64%], AKI [63%], drugs [41%], bleeding [36%], hyponatremia [22%], TIPS [12%], and constipation [1%]), and 82% had multiple concomitant PF. In‐hospital mortality was 50%, and median TFS was 0.8 months. In multivariate analysis, factors associated with death or liver transplantation were the number of PF, MELD and Child–Pugh scores, ACLF, AKI and infection. Hepatic encephalopathy reoccurred in 42% (median delay of 30 months). Conclusion: All patients had precipitating factor of hepatic encephalopathy, 82% of them having multiple concomitant precipitating factors. Concomitant multiple precipitating factors were associated with death or liver transplantation. A systematic screening for all precipitating factors of hepatic encephalopathy should be proposed for cirrhotics admitted to intensive care unit.


  • TIPS and hepatic encephalopathy in patients with cirrhosis

    by Pauline Bozon-Rivière, Marika Rudler, Nicolas Weiss, Dominique Thabut

    Despite a better understanding in its prognosis and pathogenesis, hepatic encephalopathy (HE) remains one of the major complications of Transjugular Intrahepatic Portosystemic Shunt (TIPS) with a prevalence ranging from 35 to 50%. Its epidemiology differs according to the indication for TIPS (salvage/rescue TIPS, preemptive (pTIPS) or elective TIPS). In salvage/rescue TIPS, the prognosis is linked to that of bleeding, and HE should not be a contraindication to TIPS, especially as bleeding is a common precipitating factor of HE. In pTIPS, i.e. TIPS performed within the 72 h after stabilization of acute variceal bleeding in high-risk patients, the risk rebleeding and HE is reduced, when compared to endoscopic and drugs treatment. As a consequence, the Baveno VII recommendations state that HE at admission should not be considered as a contraindication to pTIPS placement. In elective situations, such as refractory (intractable ascites (intolerance to diuretics) or resistant ascites (i.e. despite optimal diuretic treatment (spironolactone 400 mg/d and Furosemide 160 mg/d combined with low-salt treatment (< 5.2 g/day) or recurrent ascites (the need for at least 3 paracenteses per year) and secondary prophylaxis of variceal bleeding, it is recommended to systematically look for risk factors for HE, and chronic or refractory HE remain not recommended to TIPS in most centers. Chronic HE involves persistent neurological symptoms with fluctuating acute episodes. Recurrent HE refers to repeated episodes occurring within 6 months, while refractory HE is resistant to standard treatments, often requiring more aggressive management (Vilstrup et al. 2014). A careful selection of patients is mandatory before elective TIPS decision. Risk factors must be identified and corrected if possible before any TIPS decision is made. Management of HE after TIPS is based on identification of precipitating factors, curative treatment with lactulose as first-line therapy and rifaximin as second-line therapy, and nutritional management. In elective TIPS, prophylactic administration of rifaximin is recommended in order to decrease the risk of further HE development in selected patients (not in everyone, at least according to Baveno VII). Liver transplantation (LT) should be discussed with a multidisciplinary team as an alternative option to TIPS in case of high-risk of post-TIPS HE, and in case of refractory HE after TIPS.